Vaccine maker Adimmune Corp (國光生技) yesterday said it plans to start in August phase I clinical trials of its COVID-19 vaccine candidate, which effectively inhibited the growth of the novel coronavirus in preliminary animal tests last month.
Adimmune told a news conference in Taipei that it had designed and produced four prototypes of antigens to fight the virus based on its recombinant protein technology, and last month tested one prototype in a biosafety level 3 (BSL-3) lab at National Taiwan University (NTU).
After injecting the antigen into a few mice and seeing them generate antibodies, Adimmune extracted their plasma and placed it in another cell as well as the novel coronavirus to test the outcome, the company said.
Photo: Chien Hui-ju, Taipei Times
“The tests showed that the antibodies could inhibit the growth of the novel coronavirus and remained fully capable with a dilution of 1:640,” NTU Department of Clinical Laboratory Sciences and Medical Biotechnology professor Chang Sui-yuan (張淑媛) said.
The inhibition rate remained above 80 percent with a dilution of 1:1280, attesting to the strong effect of the vaccine candidate, Adimmune chairman Steve Chan (詹啟賢) said, adding that a flu vaccine is regarded as effective if its inhibition rate is higher than 80 percent with a dilution of 1:320.
The virus tested was from an isolated strain with the highest toxicity among NTU’s more than 20 isolated virus strains, Chang said.
“The tests gave us encouraging results and we feel confident. However, given that the novel coronavirus mutates, we need to run tests on more virus strains to see if the candidate will work against most of them,” she said.
The lab spent about one month setting up protocols and conducting tests, she added.
Adimmune does not know how long the vaccine candidate can protect humans from the virus, but would find out the answers in the clinical trials, Chan said.
The firm on Tuesday began the second stage of animal tests to see if the vaccine candidate would endanger mice and plans to complete the tests in October, he said.
While most vaccine developers have to wait for animal tests to be completed and for the results to be confirmed before moving on to human tests, Adimmune plans to expedite the process by applying to conduct human trials in August, Chan said.
Like other foreign regulators worldwide, Taiwan’s Food and Drug Administration has launched emergency use authorizations programs to speed up the development of a treatment for COVID-19, he said.
Adimmune has been included in the agency’s program and would be granted priority when applying for reviews or clinical trials, the company said.
After completing the animal tests’ interim analysis to make sure its candidate is safe, Adimmune would apply to conduct phase I clinical trials in August, and commence phase II and phase III trials in the first quarter next year, Chan said.
“We have to take some risks here for if the animal tests turn up negative, the phase I trial will have to stop,” he said.
The company’s goal is to start mass production of the vaccines in December if it gains approval of an emergency use authorization by the Taiwanese regulators, before gaining marketing approval next year, he said.
Shiina Ito has had fewer Chinese customers at her Tokyo jewelry shop since Beijing issued a travel warning in the wake of a diplomatic spat, but she said she was not concerned. A souring of Tokyo-Beijing relations this month, following remarks by Japanese Prime Minister Sanae Takaichi about Taiwan, has fueled concerns about the impact on the ritzy boutiques, noodle joints and hotels where holidaymakers spend their cash. However, businesses in Tokyo largely shrugged off any anxiety. “Since there are fewer Chinese customers, it’s become a bit easier for Japanese shoppers to visit, so our sales haven’t really dropped,” Ito
The number of Taiwanese working in the US rose to a record high of 137,000 last year, driven largely by Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) rapid overseas expansion, according to government data released yesterday. A total of 666,000 Taiwanese nationals were employed abroad last year, an increase of 45,000 from 2023 and the highest level since the COVID-19 pandemic, data from the Directorate-General of Budget, Accounting and Statistics (DGBAS) showed. Overseas employment had steadily increased between 2009 and 2019, peaking at 739,000, before plunging to 319,000 in 2021 amid US-China trade tensions, global supply chain shifts, reshoring by Taiwanese companies and
Taiwan Semiconductor Manufacturing Co (TSMC) Chairman C.C. Wei (魏哲家) and the company’s former chairman, Mark Liu (劉德音), both received the Robert N. Noyce Award -- the semiconductor industry’s highest honor -- in San Jose, California, on Thursday (local time). Speaking at the award event, Liu, who retired last year, expressed gratitude to his wife, his dissertation advisor at the University of California, Berkeley, his supervisors at AT&T Bell Laboratories -- where he worked on optical fiber communication systems before joining TSMC, TSMC partners, and industry colleagues. Liu said that working alongside TSMC
TECHNOLOGY DAY: The Taiwanese firm is also setting up a joint venture with Alphabet Inc on robots and plans to establish a firm in Japan to produce Model A EVs Manufacturing giant Hon Hai Precision Industry Co (鴻海精密) yesterday announced a collaboration with ChatGPT developer OpenAI to build next-generation artificial intelligence (AI) infrastructure and strengthen its local supply chain in the US to accelerate the deployment of advanced AI systems. Building such an infrastructure in the US is crucial for strengthening local supply chains and supporting the US in maintaining its leading position in the AI domain, Hon Hai said in a statement. Through the collaboration, OpenAI would share its insights into emerging hardware needs in the AI industry with Hon Hai to support the company’s design and development work, as well
RSS